Predictors of Treatment Failure Among Patients With Gunshot Wounds and Post-traumatic Stress Disorder

The 82.1% treatment failure of post-traumatic stress disorder(PTSD), associated with gunshot wounds, is related to high incidence of chronic pain syndrome as well as resistance to the PTSD treatment. Defining treatment failure predictors among the PTSD patients with gunshot extremity wounds and the following therapy would improve treatment outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gunshot Entry Wound Mental Disorders Stress Disorders, Post-Traumatic Stress Disorders, Traumatic Trauma and Stressor Related Disorders

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

About this study

It has been noted that the PTSD in military combatants results from their direct participation in military actions. The study revealed that if a military combatant was wounded during the action operation, his emotional and subjective feelings will 100% lead to the PTSD. Other scientists state about the PTSD remote treatment failure in 80% of the military combatants. The study evidences about 82.1% of the PTSD m-related wounds treatment failure, which was essential for the subsequent studies. Some authors state about treatment effectiveness of psychopharmacological drugs and psychotherapy, which is rather questionable. Traumas and somatic diseases in the PTSD patients are known to accumulate their negative effects. So, definition of the PTSD treatment failure predictors may improve treatment outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

gunshot wounds
post-traumatic stress disorder
patients who need anesthesia

Exclusion criteria

the patient has no post-traumatic stress disorder
the patient has no gunshot wounds

Treatment and study plan

Mississippi Scale for Combat-Related PTSD (M-PTSD)

Behavioral

The treatment outcome rate was assessed by the Mississippi Scale for Combat-Related PTSD (M-PTSD). A positive outcome rate is represented with the patient post-discharge positive coping, which corresponds to 94-58 points, observed in 39 patients (17.9%). A treatment failure is regarded as the absent PTSD treatment effect after discharge, which corresponds to 148-113 points, observed in 5 patients (2.3%) and psychic disorders, which correspond to 112-95 points, observed in 174 patients (79,8%).

Other names: The PTSD progress and treatment effectiveness were estimated using the Mississippi Scale for Combat-Related PTSD (M-PTSD)

Visual Analogue Scale (VAS)

Diagnostic Test

pain intensity

Other names: VAS

Douleur Neuropathique 4 questions (DN4)

Diagnostic Test

neuropathic pain component

Other names: DN4

Primary outcomes

Mississippi Scale for Combat-Related PTSD (M-PTSD)

Time frame: 1 year

The treatment outcome rate was assessed by the Mississippi Scale for Combat-Related PTSD (M-PTSD). A positive outcome rate is represented with the patient post-discharge positive coping, which corresponds to 94-58 points. A treatment failure is regarded as the absent PTSD treatment effect after discharge, which corresponds to 148-113 points and psychic disorders, which correspond to 112-95 points.

Sponsors and collaborators

Lead sponsor

Vasyl' Horoshko

Other

Collaborators

Bogomolets National Medical University

Registry information

Important dates

Study start: 2014
Primary completion: 2019
Study completion: 2020
First posted: Dec 30, 2020
Registry last updated: Dec 30, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed